Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 18/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | CTSV | O60911 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961554 | 1.00 | CAPN1 (0.60) | CAPN1L3MBTL1CTSSCTSLCTSB | |
| Dimethylamine SCHEMBL1335336 | 0.82 | CAPN1 (0.67) | CAPN1L3MBTL1CTSSCTSLCTSB | |
| SCHEMBL29961415 | 0.81 | CAPN1 (0.57) | CAPN1CTSSCTSLCTSBCTSK | |
| SCHEMBL7322673 | 0.81 | CAPN1 (0.73) | CAPN1CTSSCTSLCTSBCTSK | |
| SCHEMBL24008868 | 0.81 | CAPN1 (0.57) | CAPN1CTSSCTSLCTSBCTSK | |
| SCHEMBL6942085 | 0.81 | CAPN1 (0.73) | CAPN1CTSSCTSLCTSBCTSK | |
| SCHEMBL24009788 | 0.81 | L3MBTL1 (0.63) | CAPN1L3MBTL1CTSL | |
| SCHEMBL8443478 | 0.78 | CTSL (0.62) | CAPN1CTSSCTSLCTSK | |
| SCHEMBL24009866 | 0.77 | CAPN1 (0.52) | CAPN1CTSSCTSLCTSBCTSK | |
| SCHEMBL7501365 | 0.77 | CAPN1 (0.62) | CAPN1CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | CAPN1 1/4885L3MBTL1 2837/4885CTSS 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.